At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More
Net Sales are expected to decrease by 4.4 percent Q-o-Q (up 12.7 percent Y-o-Y) to Rs 345 crore, according to KR Choksey.
Unichem Labs logged a 12.4 percent growth in secondary sales-- made by distributors to chemists-during the December quarter when the industry grew at 5 percent, said Rakesh Parikh, VP Finance.
The drug firm reported a 3.22 percent increase in net profit to Rs. 36.2 crore for the quarter ended September 30 as sales rose.
Rakesh Parikh, VP Finance & CFO of Unichem Laboratories said exports are driving its revenue growth. Going forward, he hopes to maintain the export margins for the rest of the financial year.
According to the report on earnings preview for the quarter ended March 2012, KR Choksey expects the pharma sector will show strong performance in the domestic pharmaceuticals market mainly due to recovery in Indian pharma market.
KRChoksey has come with its December quarterly earning estimates for Pharma sector. According to the research firm, Q3FY12 is expected to be a strong quarter in terms of top-line growth mainly due to improved performance in the Indian pharmaceutical market, launch of limited competitive products in the US market & rupee depreciation.
Emkay Global Financial Services has come with its December quarterly earning estimates for pharmaceutical sector. According to the research firm the sector is expected to report a growth of 18% YoY (5% QoQ) in revenues partly driven by Rupee depreciation which is likely to be 4-5% of the overall growth.
KR Choksey has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Unichem Labs September quarter net sales are expected to go up by 11% at Rs 194 crore, year-on-year, (YoY) basis.
KRChoksey has come out with its earning estimates on pharma sector for the quarter ended June 2011. According to the research firm, Unichem Labs June quarter sales are expected to go up by 5% at Rs 196 crore, year-on-year, (YoY) basis.
Karvy Stock Broking has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Unichem Labs December quarter sales are expected to go up by 13.7% at Rs 196.5 crore, Year-on-Year, (YoY) basis.
Emkay Global Financial Services has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Unichem Labs December quarter sales are expected to go up by 11.7% to Rs 192.9 crore, Year-on-Year, (Y-o-Y) basis.